It is not the same with or without GalChimia
GalChimia has participated in BIOGREEN, an R&D project aimed at developing a concept of green biorefinery that uses biomass as raw material, specifically high yield crops not intended as food sources, to obtain high added value products such as bioplastics, celullose acetate films, and fertilizers.
The project has been developed in collaboration with the companies Norvento, Agroamb Prodalt, Biot, and Idener, and with the technological centers AINIA and CETIM. It is funded by the Centre for the Development of Industrial Technology (CDTI), the European Regional Development Fund (ERDF) and supported by the Spanish Ministry of Economy and Competitiviness. BIOGREEN was one of the projects selected by CDTI in the last edition of the INNTERCONECTA program.
GalChimia, Applus+ Laboratories, Midatech, Prochimia, the Centre for Process Innovation (CPI), and three Academic groups have participated in the research project entitled “NanoFacturing – The Development of Medium- and Large-Scale Sustainable Manufacturing Process Platforms for Clinically Compliant Solid Core Nanopharmaceuticals”.
The main objective of the project is to develop a new manufacturing platform process for solid core nanopharmaceutical products, capable of being scaled up to supply Phase III trials and beyond, which is cost-effective, safe, efficient, robust, and regulatory compliant. GalChimia has been specifically involved in the synthesis of the ligands used to bind the nanoparticles to other chemical or biological molecules. The project has been financed by the European Union through the Horizon 2020 programme.
GalChimia is part of the Neogalfarm project. Its objective is the identification of new treatments for oncology, using new therapeutic targets as well as combined therapies. The project emerged from a collaboration between AMSlab, NANOGAP, Oncostellae, and several research groups from the University of Santiago de Compostela (USC), the Health Research Institute of Santiago de Compostela (IDIS), and LEITAT.
This project was granted by the Innovation Galician Agency (GAIN) through the Conecta Pyme Program, co-financed by the European Regional Development Fund (ERDF) and supported by the Consellería de Economía, Emprego e Industria (Xunta de Galicia). The total budget is 1,076,339.63 euros.
The objective of the project is based on the elaboration of industrial protocols, using microencapsulated active products, for the detoxification of mussels. Together with the companies Pescados Marcelino, PAYPAY, Mariscos Veiro, Depuradora de Molusco La Sirena, and the academic centers ANFACO-CECOPESCA and the International Iberian Nanotechnology Laboratories (INL), GalChimia participates in the MytiTox Project.
MytiTox has been funded by the Spanish Government and the European Union through the program FEDER INNTERCONECTA 2015. The budget was 1.461.272,00 euros.
GalChimia, Novozyme, Biochemize, Drop-Tech and four Academic groups participate in the research project HotDrops, whose goal is to develop a new ultrahigh-throughput platform to search for new biocatalysts, with which large enzyme-variant libraries that were previously challenging to handle can be screened. Single bacterial cells or in-vitro transcription/translation systems can be compartmentalized into droplets, each expressing a different gene library variant. This project combines three sciences: enzymology, microfluid technology, and organic chemistry. The project has been funded by the European Union through the Seventh Framework Programme (FP7). Click here for more info
GalChimia, Oncostellae, and AMSLab participates in the research project Oncogalfarma, whose goal is to develop new complementary therapies for the treatment of oncological diseases. The research is centered in the fields of inhibitors of protein–protein interactions (PPI) and nuclear receptors. The project has been financed by the Government of Galicia and co-financed by the European Regional Development Fund through the subprogramme CONECTA PEME. The total funding granted is €189,943.59. Click here for more information
The project “Light emitting nanomolecules for biomedical diagnostics applications (LENBDA)” was intended to study the industrial use of a biomolecule detection system based on highly specific luminescent nanoemitters. The system offers a complete solution for the detection of biomolecules in a specific, interference-free way. To accomplish this goal, a fully functional prototype of the diagnostic kit will be developed to be used in pathology labs, so that no additional equipment will be needed. At the final stage, the project will be validated against tumour cell lines available in tissue banks. The project has been financed by the government of Galicia and the European Regional Development Fund through the subprogramme CONECTA PEME. The total funding granted is €161,622.94.
GalChimia is a member of the consortium Humanfarma, whose goal is the development of new active compounds for drug discovery through translational research directly in patient samples. The project, which has a budget of €4.1 M and has been partially financed by the Ministry of Economy and Competitiveness under the INNPACTO subprogramme, also involves the participation of the University of Santiago de Compostela (USC), the Barcelona Science Park (PCB), and three biotech companies: Oryzon Genomics, Vivia Allosterics and Vivia Biotech, which is the coordinator of the project.
The biotechnology company Alfama, with sites in Lisbon and Boston, is the world leader in CO-releasing molecules (CORMs), compounds with powerful vasodilatation activity. GalChimia has partnered with Alfama to develop CORMs for Postoperative Ileus (POI), a condition usually found in patients who have undergone surgery. GalChimia’s synthetic expertise complements the Alfama’s deep biological knowledge of CORMs.
This project was developed in close collaboration with Esteve Quimica and it was funded by a national grant from the CDTI. The main objective was to evaluate and develop innovative routes of synthesis for generic products or APIs closed to patent expiration. To do so, it is important to identify new routes with a clear competitive advantage in terms of cost or yield, and/or using cheaper intermediates or catalysts, and/or using cleaner and more efficient technologies.